Perrigo Co (BSP:P1RG34) Debt-to-Equity : 1.04 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Perrigo Co Debt-to-Equity?

Perrigo Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was R$2,441 Mil. Perrigo Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was R$23,882 Mil. Perrigo Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was R$25,286 Mil. Perrigo Co's debt to equity for the quarter that ended in Sep. 2024 was 1.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Perrigo Co's Debt-to-Equity or its related term are showing as below:

BSP:P1RG34' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.49 Med: 0.65 Max: 1.04
Current: 1.04

During the past 13 years, the highest Debt-to-Equity Ratio of Perrigo Co was 1.04. The lowest was 0.49. And the median was 0.65.

BSP:P1RG34's Debt-to-Equity is ranked worse than
86.92% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs BSP:P1RG34: 1.04

Perrigo Co Debt-to-Equity Historical Data

The historical data trend for Perrigo Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Debt-to-Equity Chart

Perrigo Co Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.58

0.66

0.72

0.85

Perrigo Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.90	0.85	0.87	0.89	1.04

Competitive Comparison of Perrigo Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perrigo Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Perrigo Co's Debt-to-Equity falls into.

Perrigo Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Perrigo Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2158.852	+	17799.993)	/	23361.756
	=	0.85

Perrigo Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2440.508	+	23882.316)	/	25285.595
	=	1.04

Perrigo Co (BSP:P1RG34) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Perrigo Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Perrigo Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Perrigo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (BSP:P1RG34) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PRGO:USA 0Y5E:UK PIG:Germany PIG:Germany

Address

The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74

Website

https://www.perrigo.com

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Perrigo Co Headlines

No Headlines